Sigma Labs is Allowed US Patent for Process Control Systems During Additive Manufacturing Operations
May 15, 2018 | Categories: Member News
SANTA FE, N.M. – May 15, 2018 – Sigma Labs, Inc. (NASDAQ: SGLB) (“Sigma” or the “Company”), a provider of quality assurance software under the PrintRite3D® brand, today announced that the Company was allowed a seminal patent entitled “Method and System for Monitoring Additive Manufacturing Processes.” The patent provides protection for methods of assuring part quality using real time data from multiple sensor types. The patent enables serial production applications through real time tracking and reporting of process consistency and part repeatability. The patent being allowed is for the first application filed in a series of 18 patent applications submitted by Sigma over these past 5 years in the general domain of in process quality assurance.
Mark Cola, Sigma co-founder, President and Chief Technology Officer, states “Our PrintRite3D® technology can be used in many AM applications and helps our customers to increase their product time to market (TTM) through a better understanding of their process variance and means by which to control it. Looking to the future, PrintRite3D® will allow our customers to achieve product yield improvements during serial production through use of our proprietary software algorithms.”
Sigma, the industry’s leading provider of in-process melt pool quality assurance software, continues to work with leaders in metal additive manufacturing such as Siemens, Woodward and Solar Turbines to incorporate its PrintRite3D® technology across multiple additive manufacturing markets. Sigma has various other patents pending covering its PrintRite3D® technology.
About Sigma Labs
Sigma Labs, Inc. is a provider of quality assurance software under the PrintRite3D® brand and a developer of advanced, in-process, non-destructive quality assurance software for commercial firms worldwide seeking productive solutions for advanced manufacturing. For more information please visit us at www.sigmalabsinc.com.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K (including but not limited to the discussion under “Risk Factors” therein) filed with the SEC on April 17, 2018 and which may be viewed at http://www.sec.gov.
Investor Relations Contact:
Courtesy of Sigma Labs